Navigation Links
Tarantula venom-based MD therapy to be advanced by UB scientists' biotech company
Date:12/29/2009

BUFFALO, N.Y. -- University at Buffalo biophysicists have found a protein in tarantula venom that shows promise as a potential therapy for muscular dystrophy (MD). They have formed a start-up biotech company in Buffalo -- Rose Pharmaceuticals -- to advance the drug to clinical trials.

Fredrick Sachs, PhD, professor of physiology and biophysics at the University at Buffalo, and colleagues in his laboratory, discovered the peptide, called GsMTx4.

Therapies for muscular dystrophy are classed as "orphan drugs" by the FDA, allowing a shorter testing period than normal drugs. Sachs said he anticipates Rose Pharmaceuticals may be able to obtain FDA approval of the peptide for human use within two years.

The new company is named for "Rose," the pet tarantula that has been in residence in Sachs' lab for nearly 20 years.

The first target of the peptide is MD, a condition Sachs has been investigating for several years, but the peptide also has potential as a therapy for several other conditions, such as neuropathic pain and atrial fibrillation. Formation of the company was motivated by the goal of finding an MD therapy for the grandson of Sachs' friend Jeffrey Harvey.

The start-up is a collaboration between Sachs, Harvey, Thomas Suchyna, PhD, and Philip Gottlieb, PhD. Suchyna and Gottlieb, UB research scientist and UB research associate professor, respectively, have been working with Sachs at the university for several years to develop the peptide. Their work was supported by a grant from UB's Interdisciplinary Research and Creative Activities Fund.

In collaboration with Eric Hoffman, PhD, director of the Wellstone Muscular Dystrophy Center at Children's National Medical Center in Washington, D.C., the team tested the effect of GsMTx4 on MD mice extensively. Results showed that the drug increased muscle strength and caused no mortality, morbidity or toxicity.

Rose Pharmaceuticals now is concentrating on developing methods to administer the drug. The peptide and its mirror image are covered by U.S. patents obtained by UB's Office of Science, Technology Transfer and Economic Outreach (STOR), and licensed to Rose Pharmaceuticals. Sachs noted that there are no other drugs known to act specifically on mechanosensitive ion channels, the target of GsMTx4.

"Unlike most drugs, GsMTx4 seems to generate only positive side effects," said Sachs. "In addition to its effectiveness in MD, it inhibits atrial fibrillation, a cardiac arrhythmia that affects 2 million Americans, and for which there currently is no reliable drug therapy.

"In a second application, research groups in Korea and UC San Francisco have shown that GsMTx4 can inhibit mechanically induced pain (pain originating in nerve fibers)," he said. "This therapy is at least half as effective as morphine, but does not act on the brain, only at the site of increased sensitivity." Mark Kristal, PhD, UB professor of psychology, has been collaborating on the pain testing.

GsMTx4 appears to have additional applications. Robert Plunkett, MD., UB associate professor of neurosurgery, has shown that the peptide stimulates neuronal growth, and may be useful for the treatment of Parkinson's disease.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Related biology news :

1. Successful stem cell therapy for treatment of eye disease
2. Gene therapy and stem cells save limb
3. New therapy targets for amyloid disease
4. New understanding about mechanism for cell death after stroke leads to possible therapy
5. Duke develops nano-scale drug delivery for chemotherapy
6. Caltech researchers show efficacy of gene therapy in mouse models of Huntingtons disease
7. USU scientists report major advance in human antibody therapy against deadly Nipah virus
8. Patients in Europe benefit from new radiation therapy
9. LX211 highlighted as potential disease modifying therapy for non-infectious uveitis
10. Research needed to learn which DCIS patients may be candidates for less invasive therapy
11. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... Nov. 14, 2016  Based on its ... Frost & Sullivan recognizes FST Biometrics with ... for Visionary Innovation Leadership. FST Biometrics emerged ... identification market by pioneering In Motion Identification ... instant, seamless, and non-invasive verification. This patented ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In ... Sciences a team of scientists in Guangzhou, China ... that expression of NR2F6 in patients with early cervical cancer ... patient,s cervical cancer tissue as well as in the normal ... an interesting study and the first that I am aware ...
(Date:12/7/2016)... ... December 07, 2016 , ... Proscia Inc., ... new service to enable rapid migration of large pathology data sets to the ... the factors limiting adoption of digital pathology. Proscia’s free massive dataset migrator makes ...
(Date:12/7/2016)... Francisco, CA (PRWEB) , ... ... ... leader uBiome is opening applications to an early access program for SmartBiome ... of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of hundreds ...
(Date:12/6/2016)... Texas , Dec. 6, 2016 The ... for its adoption of arnica ( Arnica montana ... support to ABC,s HerbMedPro database, a ... important scientific and clinical research data on the ... popular herbs. Naturopathica, a wellness company ...
Breaking Biology Technology: